To determine if tumor recurrence in glioblastoma patients who have undergone TMZ chemotherapy is associated with an increase in de novo purine synthesis enzyme expression, we performed IHC to determine the expression of metabolic enzymes DHFR, MTHFD2, and PAICS in ID-1-high patients. Here, MTHFD2 is linked to neoplasm.